logo

For the Inventor, By the Inventor

Monza, Italy

Elso Manghisi

This inventor holds 20 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Istituto Luso Farmaco D'italia, Istituto Luso Farmaco D'italia S.r.l., Instituto Luso Farmaco D'italia S.r.l.. Active years: 1976-1996.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elso Manghisi. Retrieved from https://idiyas.com/inventor/elso-manghisi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 20

% Patents Active = 100.0

Average Co-Inventor Count = 2.6

ph-index = 5

Forward Citations = 109(Granted Patents)


Location History:

  • Monza (Milan), IT (1976 - 1978)
  • Monza, IT (1976 - 1988)
  • Milan, IT (1976 - 1996)

Company Filing History:

goldMedal7 out of 18 
 
Istituto Luso Farmaco D'italia
 patents
silverMedal5 out of 5 
 
Istituto Luso Farmaco D'italia S.r.l.
 patents
bronzeMedal4 out of 4 
 
Instituto Luso Farmaco D'italia S.r.l.
 patents
4. 2 out of 2 
 
Instituto Luso Farmaco D'italia S.p.a.
 patents
5. 1 out of 1 
 
Lusofarmaco Istituto Lusofarmaco D'italia Spa
 patent
6. 1 out of 834,708 
Other
 patents

Years Active: 1976-1996

Loading Chart...
Areas of Expertise:
Benzothiazepinone Derivatives
Angiotensin II Antagonists
Imidazolone Derivatives
Thiazole Compounds
Phenoxyalkylamines
Dioxole Derivatives
Beta-Aminoketones
Pharmaceutical Compositions
20 patents (USPTO):Explore Patents
1. 5571807 - 1,5 benzothiazepinone dervatives their preparation and pharmaceutical use (1996-11-05),
2. 5565464 - Compounds having angiotensine II antagonistic activity (1996-10-15),
3. 5059601 - Imidazolone derivatives with activity on central nervous system and (1991-10-22),
4. 4948797 - 2,2-disubstitued 2,3-dihydro-1,4-benzodioxin derivatives having (1990-08-14),
5. 4761422 - (2-amino-4-aryl-thiazole-5-yl)ethanols and their derivatives having (1988-08-02),
6. 4587242 - Sulfonic resins having a therapeutical activity, preparation thereof and (1986-05-06),
7. 4584321 - 3-(3-Hydroxybutoxy)-1-butanol in pharmaceutical compositions (1986-04-22),
8. 4533748 - Process for the optical resolution of the (1985-08-06),
9. 4262006 - Substituted 2-phenylamino-imidazolines-(2) and pharmaceutical (1981-04-14),
10. 4235904 - 4-Aryl-5-piperazinoalkyl-1,3-dioxol-2-ones, and compositions (1980-11-25),
11. 4115585 - Esters of (1978-09-19),
12. 4091222 - 2,2 Disubstituted-benzodioxoles (1978-05-23),
13. 4061637 - Certain 4-aryl-5-(4-phenylpiperazino)alkyl-4-thiazolin-2-ones (1977-12-06),
14. 4046762 - Esters and amides of 3-aryl-1,4 benzodioxan-2-carboxylic acids (1977-09-06),
15. 3988475 - Phenoxyalkylamines (1976-10-26),

Title: Inventor Elso Manghisi: Pioneering Innovations from Monza, Italy

Introduction: Elso Manghisi is a distinguished inventor hailing from the vibrant city of Monza, Italy. With a passion for creativity and problem-solving, he has made significant contributions to the field of innovation.

Latest Patents: Elso Manghisi holds several groundbreaking patents in various industries, showcasing his versatility and ingenuity in developing novel solutions to complex challenges.

Career Highlights: Throughout his illustrious career, Elso Manghisi has consistently pushed the boundaries of traditional thinking, leading to the creation of revolutionary technologies that have had a lasting impact on society.

Collaborations: Elso Manghisi has collaborated with leading experts and organizations in the innovation space, fostering a culture of knowledge-sharing and collective growth to drive forward progress in the field.

Conclusion: Elso Manghisi's dedication to innovation and his relentless pursuit of excellence continue to inspire aspiring inventors worldwide, leaving an indelible mark on the landscape of technological advancement.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…